A Review of New Medications and Future Directions of Medical Therapies in Glaucoma

REFERENCES

• Tham Y-C, Li X, Wong TY, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040. Ophthalmology. 2014;121(11):2081–2090. doi:10.1016/j.ophtha.2014.05.013.
   PubMed Web of Science ®Google Scholar
• Glaucoma. BCSC Basic and Clinical Science Course 2016–2017. American Academy of Ophthalmology, San Francisco, CA. 2016.
   Google Scholar
• Realini T. A history of glaucoma pharmacology. Optometry Vision Sci. January 2011;88(1):36–38. doi:10.1097/OPX.0b013e3182058ead.
   PubMed Web of Science ®Google Scholar
• Kazemi A, McLaren JW, Kopczynski CC, Heah TG, Novack GD, Sit AJ. The effects of netarsudil ophthalmic solution on aqueous humor dynamics in a randomized study in humans. J Ocul Pharmacol Ther. 2018;34(5):380–386. doi:10.1089/jop.2017.0138.
   PubMed Web of Science ®Google Scholar
• Rao PV, Pattabiraman PP, Kopczynski C. Role of the rho GTPase/rho kinase signaling pathway in pathogenesis and treatment of glaucoma: bench to bedside research. Exp Eye Res. 2017;158:23–32. doi:10.1016/j.exer.2016.08.023.
   PubMed Web of Science ®Google Scholar
• Lin CW, Sherman B, Moore LA, et al. Discovery and preclinical development of netarsudil, a novel ocular hypotensive agent for the treatment of glaucoma. J Ocul Pharmacol Ther. 2018;34(1–2):40–51. doi:10.1089/jop.2017.0023.
   PubMed Web of Science ®Google Scholar
• Levy B, Ramirez N, Novack GD, et al. Ocular hypotensive safety and systemic absorption of AR-13324 ophthalmic solution in normal volunteers. Am J Ophthalmol. 2015;159:980–985. doi:10.1016/j.ajo.2015.01.026.
   PubMed Web of Science ®Google Scholar
• Bacharach J, Dubiner HB, Levy B, Kopczynski CC, Novack GD. AR-13324-CS202 study group. Double-masked, randomized, dose-response study of AR-13324 vs. latanoprost in patients with elevated intraocular pressure. Ophthalmology. 2015;122(2):302–307. doi:10.1016/j.ophtha.2014.08.022.
   PubMed Web of Science ®Google Scholar
• Serle JB, Katz LJ, McLaurin E, et al. Two phase 3 clinical trials comparing the safety and efficacy of netarsudil to timololin patients with elevated intraocular pressure. Am J Ophthalmol. 2018;186:116–127. doi:10.1016/j.ajo.2017.11.019.
   PubMed Web of Science ®Google Scholar
• Khouri AS, Serle JB, Bacharach J, et al. Once-daily netarsudil vs twice-daily timolol in patients with elevated intraocular pressure, the randomized phase 3 ROCKET-4 study. Am J Ophthalmol. 2019;204:97–104. doi:10.1016/j.ajo.2019.03.002.
   PubMed Web of Science ®Google Scholar
• Mehran NA, Sinha S, Razeghinnejad R. New glaucoma medications: latanoprsotene bunod, netarsudil, and fized combination netarsudil-latanoprost. Eye (Lond). January 2020;34(1):72–88. doi:10.1038/s41433-019-0671-0. Epub 2019 Nov 6.
   PubMed Web of Science ®Google Scholar
• Fernandez MM. Reticular epithelial edema in edematous corneas treated with netarsudil. Opthahlmology. 2018 Nov;124(11):1709. doi:10.1016/j.ophtha.2018.08.004.
   Google Scholar
• Chen TC, Jurkunas U, Chodosh J. JAMA ophthalmology clinical challenge: a glaucoma patient with corneal edema. JAMA Ophthalmol. 2020 Aug 1;138(8):917-918.
   Google Scholar
• Cavet ME, Vittitow JL, Impagnatiello F, et al. Nitric oxide (NO): an emerging target for the treatment of glaucoma. Invest Ophthalmol Vis Sci. 2014;55(8):5005–5015. doi:10.1167/iovs.14-14515.
   PubMed Web of Science ®Google Scholar
• Hoy SM. Latanoprostene bunod ophthalmic solution 0.024%: a review in open angle glaucoma and ocular hypertension. Drugs. 2018;78:773–780. doi:10.1007/s40265-018-0914-6.
   PubMed Web of Science ®Google Scholar
• Bausch & Lomb. Clinical Review(s): VYZULTA (Latanoprostene Bunod Ophthalmic Solution) 0.024% Product Monograph. Bridgewater, NJ: Bausch & Lomb, a division of Valeant Phar- maceuticals North America LLC; 2017.
   Google Scholar
• Araie M, Sforzolini BS, Vittitow J, Weinreb RN. Evaluation of the effect of latanoprostene bunod ophthalmic solution, 0.024% in lowering intraocular pressure over 24 h in healthy Japanese subjects. Adv Ther. 2015;32:1128–1139. doi:10.1007/s12325-015-0260-y.
   PubMed Web of Science ®Google Scholar
• Weinreb RN, Ong T, Scassellati Sforzolini B, Vittitow JL, Singh K, Kaufman PL. A randomised, controlled comparison of lata-noprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study. Br J Ophthalmol. 2015;99:738–745. doi:10.1136/bjophthalmol-2014-305908.
   PubMed Web of Science ®Google Scholar
• Liu JHK, Slight JR, Vittitow JL, Sforzolini BS, Weinreb RN. Efficacy of latanoprostene bunod 0.024% compared with timolol 0.5% in lowering intraocular pressure over 24 hours. Am J Ophthalmol. September 2016;169:249–257. doi:10.1016/j.ajo.2016.04.019.
   PubMed Web of Science ®Google Scholar
• Weinreb RN, Scassellati Sforzolini B, Vittitow J, Liebmann J. Latanoprostene bunod 0.024% versus timolol maleate 0.5% in subjects with open-angle glaucoma or ocular hypertension: the APOLLO study. Ophthalmology. 2016;123:965–973. doi:10.1016/j.ophtha.2016.01.019.
   PubMed Web of Science ®Google Scholar
• Medeiros FA, Martin KR, Peace J, Scassellati Sforzolini B, Vittitow JL, Weinreb RN. Comparison of latanoprostene bunod 0.024% and timolol maleate 0.5% in open-angle glaucoma or ocular hypertension: the LUNAR study. Am J Ophthalmol. 2016;168:250–259. doi:10.1016/j.ajo.2016.05.012.
   PubMed Web of Science ®Google Scholar
• Weinreb RN, Liebmann JM, Martin KR, Kaufman PL, Vittitow JL. Latanoprostene bunod 0.024% in subjects with open-angle glaucoma or ocular hypertension: pooled phase 3 study findings. J Glaucoma. January 2018;27(1):7–15. doi:10.1097/IJG.0000000000000831.
   PubMed Web of Science ®Google Scholar
• Kawase K, Vittitow JL, Weinreb RN, Araie M. Long-term safety and efficacy of latanoprostene bunod 0.024% in Japanese subjects with open-angle glaucoma or ocular hypertension: the JUPITER study. Adv Ther. 2016;33:1612–1627. doi:10.1007/s12325-016-0385-7.
   PubMed Web of Science ®Google Scholar
• Lewis RA, Levy B, Ramirez N, Kopczynski CC, Usner DW, Novack GD. Fixed-dose combination of AR-13324 and latanoprost: a double-masked, 28-day, randomised, controlled study in patients with open-angle glaucoma or ocular hypertension. Br J Ophthalmol. 2016;100:339–344. doi:10.1136/bjophthalmol-2015-306778.
   PubMed Web of Science ®Google Scholar
• Asrani S, Robin AL, Serle JB, et al. Netarsudil/latanoprost fixed-dose combination for elevated intraocular pressure: 3-month data from a randomized phase 3 trial. Am J Ophthalmol. 2019;S0002-9394:30284.
   Google Scholar
• Walters TR, Ahmed IIK, Lewis RA, et al. Once daily netarsudil/latanoprost fixed-dose combination for elevated intraocular pressure in the randomized phase 3 MERCURY-2 study. Ophthalmol Glaucoma. 2019;2:280–289. doi:10.1016/j.ogla.2019.03.007.
   PubMedGoogle Scholar
• Radell JE, Serle JB. Netarsudil/latanoprost fixed-dose combination for the treatment of open-angle glaucoma or ocular hypertension. Drugs Today (Barc). September 2019;55(9):563–574. doi:10.1358/dot.2019.55.9.3039670.
   PubMed Web of Science ®Google Scholar
• Karmel M. Sustained-release travoprost: data at 12 months. News in review: commentary and perspective. Eyenet Mag. October 2018:21–23.
   Google Scholar
• Lewis RA, Christie WC, Day DG, et al.; Bimatoprost SR Study Group. Bimatoprost sustained-release implants for glaucoma therapy: 6-month results from a phase I/II clinical trial. Am J Ophthalmol. Mar 2017;175:137–147. doi:10.1016/j.ajo.2016.11.020.
   PubMed Web of Science ®Google Scholar
• Eyewire News. FDA accepts allergan’s NDA for bimatoprost SR in patients with glaucoma. https://eyewire.news/articles/fda-accepts-allergans-nda-for-bimatoprost-sustained-release-in-patients-with-open-angle-glaucoma-or-ocular-hypertension/. Published July 17, 2019. Accessed December 30, 2019.
   Google Scholar
• Lee SS, Dibas M, Almazan A, Robinson MR. Dose-response of intracameral bimatorpost sustained-release implant and topical bimatoprost in lowering intraocular pressure. J Ocul Pharmacol Ther. 2019;35(3):138–144. doi:10.1089/jop.2018.0095.
   PubMed Web of Science ®Google Scholar
• Tsai JC, Comprehensive A. A comprehensive perspective on patient adherence to topical glaucoma therapy. Ophthalmology. 2009;116(11):S30- S36. doi:10.1016/j.ophtha.2009.06.024.
   PubMed Web of Science ®Google Scholar
• Neelakantan A, Vaishnav HD, Iyer SA, Sherwood MB. Is addition of a third of fourth antiglaucoma medication effective? J Glaucoma. April 2004;13(2):130–136. doi:10.1097/00061198-200404000-00008.
   PubMed Web of Science ®Google Scholar
• Vislisel J. Cornea verticillata. Eyerounds.org, The University of Iowa. January 2016. https://webeye.ophth.uiowa.edu/eyeforum/atlas/pages/Verticillata/index.htm
   Google Scholar